Accepted Manuscript



An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities

Bryan Koci, Gregory Luerman, Anika Duenbostell, Ralf Kettenhofen, Heribert Bohlen, Luke Coyle, Brian Knight, Warren Ku, Walter Volberg, Joseph R. Woska, Martha P. Brown

PII: S0041-008X(17)30229-6
DOI: doi: 10.1016/j.taap.2017.05.023
Reference: YTAAP 13956

To appear in: *Toxicology and Applied Pharmacology*

Received date: 27 March 2017
Revised date: 8 May 2017
Accepted date: 20 May 2017

Please cite this article as: Bryan Koci, Gregory Luerman, Anika Duenbostell, Ralf Kettenhofen, Heribert Bohlen, Luke Coyle, Brian Knight, Warren Ku, Walter Volberg, Joseph R. Woska, Martha P. Brown , An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Ytaap(2017), doi: 10.1016/j.taap.2017.05.023

An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves *in vitro* prediction of *in vivo* cardiotox liabilities

Bryan Koci[3*], Gregory Luerman[1], Anika Duenbostell[2], Ralf Kettenhofen[2], Heribert Bohlen[2], Luke Coyle[3], Brian Knight[3], Warren Ku[3], Walter Volberg[3], Joseph R. Woska, Jr.[3] and Martha P. Brown[3]

[1]Axiogenesis Inc, Plymouth Meeting, PA, USA, [2]Axiogenesis AG, Cologne, Germany, [3]Boehringer-Ingelheim Pharmaceuticals, Ridgefield, CT, USA

*Corresponding author. *E-mail address:* lake23trout@yahoo.com

Abbreviations: CiPA, comprehensive in vitro proarrhythmia assay; hIPSC-CMs, human induced pluripotent stem cell cardiomyocytes; HDAC, histone deacetylase inhibitors